Compare
Cadrenal Therapeutics, Inc. vs Pulmatrix, Inc. vs International Stem Cell Corp vs Bio-Path Holdings, Inc.
| Latest fiscal year | Cadrenal Therapeutics, Inc. CVKD | Pulmatrix, Inc. PULM | International Stem Cell Corp ISCO | Bio-Path Holdings, Inc. BPTHLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | n/a | n/a | $9.10M | n/a |
| Revenue growth (YoY) | n/a | n/a | +0.2% | n/a |
| Gross margin | n/a | n/a | 55.7% (computed) | n/a |
| Operating margin | n/a | n/a | -2.9% | n/a |
| Net margin | n/a | n/a | -4.6% | n/a |
| Net income | -$13.24M | -$5.16M | -$418.0K | -$9.89M |
| EPS (Diluted) | -$6.64 | -$1.41 | -$0.05 | -$4.12 |
| Operating cash flow | -$12.60M | -$5.43M | $8.0K | -$10.57M |
| Free cash flow | -$12.61M | n/a | -$35.0K | n/a |
| Cash & equivalents | $4.01M | $4.09M | n/a | n/a |
| Total assets | $4.33M | $4.14M | $4.82M | $3.88M |
| Total liabilities | $1.59M | $329.0K | $4.58M | $3.73M |
| Shareholders' equity | $2.74M | $3.81M | -$4.06M | $154.0K |
| Return on year-end equity | -483.3% | -135.5% | n/a | n/m |
| Shares outstanding | 2.34M | 3.65M | 8.00M | 5.77M |
Revenue, most recent five fiscal years
| Fiscal year | Cadrenal Therapeutics, Inc. | Pulmatrix, Inc. | International Stem Cell Corp | Bio-Path Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $7.81M Ended 2024-12-31 | $9.10M Ended 2025-12-31 | $0 Ended 2018-12-31 |
| 1 year earlier | n/a | $7.30M Ended 2023-12-31 | $9.09M Ended 2024-12-31 | $37.0K Ended 2017-12-31 |
| 2 years earlier | n/a | $6.07M Ended 2022-12-31 | $7.79M Ended 2023-12-31 | $13.0K Ended 2016-12-31 |
| 3 years earlier | n/a | $5.17M Ended 2021-12-31 | $8.18M Ended 2022-12-31 | $0 Ended 2015-12-31 |
| 4 years earlier | n/a | $12.63M Ended 2020-12-31 | $7.18M Ended 2021-12-31 | $0 Ended 2014-12-31 |